Providing Practical AI For Drug Development
A solutions-led platform to identify and accelerate drug development
Uniquely deployable at any stage from pre-clinical through regulatory approval and beyond, BioPhy leverages robust data, pending patents, and world-renowned AI expertise to drive unprecedented speed and value from early-stage biotech to Big Pharma.
-
proven accuracy
-
clinical trials processed
-
improvement in speed & efficiency
Portfolio Growth
•
Manufacturing
•
Practical AI
•
R&D
•
Regulatory
•
Portfolio Analysis
•
Quality Assurance
•
Custom AI Solutions
•
Competitive Intelligence
•
Clinical Operations
•
Portfolio Growth • Manufacturing • Practical AI • R&D • Regulatory • Portfolio Analysis • Quality Assurance • Custom AI Solutions • Competitive Intelligence • Clinical Operations •
An Industry Problem
Drug development is slow, inefficient and risky.
Long timelines, soaring costs, entrenched frameworks, and prohibitive failure rates obstruct (derail) biopharma’s pipeline productivity and progress in drug development. It simply takes too long, costs too much, and sees too many failures to identify, accelerate and deliver the most promising new treatments.
Our Results
Redefining outcomes…together.
BioPhy provides a collaborative, iterative approach that leverages practical AI delivering tangible results aligned to R&D, regulatory, manufacturing, and portfolio growth. Our solutions are actively used across all 35,000+ clinical trials with a validated 80%+ accuracy predicting 1600+ clinical trial outcomes over ~3 years, while achieving a substantial improvement in protocol design times, development duration and asset valuation for our clients, outperforming both human experts and other AI solutions. BioPhy is led by Dr. David Latshaw II, ex senior scientist at J&J leading their AI advanced technologies center of excellence and a globally recognized expert at the intersection of AI and Drug Development.
Probability of regulatory approval.
Our two platforms work in parallel to identify the highest potential candidates via validated predictive insights while dynamically generating the intelligence to progress them efficiently through each development stage. This end-to-end approach tackles roadblocks from pre-clinical through approvals and beyond.
Our Solutions
Here at BioPhy we have two core AI solutions, predictive and generative. BioLogicAI is our predictive intelligence solution that rapidly analyzes clinical trial data to accurately forecast study outcomes, optimizing development decisions on the most promising therapeutics. BioPhyRx is our proprietary generative AI that provides on-demand scientific and clinical guidance, allowing experts to enhance productivity across regulatory, quality, and operational workflows - accelerating core drug development functions through automation.
What People Are Saying
“Predictive modeling has given us unparalleled insights into new targets, safety, efficacy and clinical trial optimization.”
— Clinical Stage Biotech
“BioPhy AI is producing a commercial solution in regulatory and GxP that no other company has provided.”
— Large European Pharma
“An end-to-end solution that has impacted every stage of our drug development.”
— CRO
The BioPhy Management Team
-
![]()
Dave Latshaw II, Ph.D.
Chief Executive & Scientific Officer
-
![]()
Steven Truong
Chief Financial Officer & President
-
![]()
Caitlin Jaye-Yan
Chief Compliance Officer & General Counsel
-
![]()
Lewis Katz
Chief Operating Officer
-
![]()
Daniel Sciubba, MD
Chief Medical Officer
-
![Scott Kobayashi]()
Scott Kobayashi
Senior Vice President
